[The effect of adjuvant combined chemo/immunotherapy on immunological parameters and clinical course in patients with breast carcinoma].
In 61 breast cancer patients the effect of an combined adjuvant chemo-/immunotherapy with thymopentin (Timunox, Cilag) on different parameters of cell-mediated immunity (Leucocyte Migration Inhibition Test, serum level of tumor necrosis factor alpha, IL 2, Interferon alpha and distribution of lymphocyte subsets in the peripheral blood) and the clinical course of disease was evaluated and compared to patients receiving only chemotherapy. In cancer patients additionally treated with thymopentin an increase of the interferon alpha serum level could be observed, whereas the other parameters examined did not change. In the control group the percentage of T helper cells decreased under chemotherapy (p less than 0.05). Due to the short time of observation of 49 months until now no significant changes concerning the disease free interval and the time of survival between both groups could be found. Possibly the additional administration of thymopentin in breast cancer patients at least leads to a reduction of the immunosuppressive side effects of an adjuvant chemotherapy.
Universitäts-Frauenklinik, Bonn.
P
P
Mallmann
D
D
Krebs
D001943:Breast Neoplasms / Q000276:immunology / Q000628:therapy*; D002464:Cell Migration Inhibition; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016898:Interferon-alpha / Q000737:chemistry; D007376:Interleukin-2 / Q000737:chemistry; D016305:Thymopentin / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000737:chemistry
D016898:Interferon-alpha; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D016305:Thymopentin
Einfluss einer adjuvanten kombinierten Chemo-/Immuntherapie auf immunologische Parameter und den klinischen Verlauf bei Patientinnen mit Mammakarzinom.